SCHEMBL624327

SCHEMBL624327

O=Cc1ccc(-c2cccc(Cl)c2)o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.60
KDM4E B2RXH2 5/20 0.60
POLB P06746 4/20 0.60
TDP1 Q9NUW8 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
MAPT P10636 8/20 0.59
HPGD P15428 5/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
HSD17B10 Q99714 1/20 0.56
NPSR1 Q6W5P4 3/20 0.56
HTT P42858 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MITF O75030 1/20 0.56
ALOX15 P16050 1/20 0.56
ALOX12 P18054 1/20 0.56
RECQL P46063 1/20 0.56
CCR6 P51684 1/20 0.56
GPR55 Q9Y2T6 1/20 0.56
NPC1 O15118 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5468753 0.84 ALDH1A1 (0.55) ALDH1A1KDM4EPOLBTDP1L3MBTL1
SCHEMBL25977802 0.81 ALDH1A1 (0.62) ALDH1A1KDM4EPOLBTDP1L3MBTL1
SCHEMBL8243143 0.81 ALDH1A1 (0.67) ALDH1A1KDM4EPOLBTDP1L3MBTL1
SCHEMBL14608669 0.79 ALDH1A1 (0.60) ALDH1A1KDM4EPOLBTDP1L3MBTL1
SCHEMBL14324716 0.79 ALDH1A1 (0.60) ALDH1A1KDM4EPOLBTDP1L3MBTL1
SCHEMBL14324626 0.79 ALDH1A1 (0.60) ALDH1A1KDM4EPOLBTDP1L3MBTL1
SCHEMBL2324212 0.79 ALDH1A1 (0.60) ALDH1A1KDM4EPOLBTDP1L3MBTL1
SCHEMBL7328684 0.79 ALDH1A1 (0.64) ALDH1A1KDM4EPOLBTDP1L3MBTL1
SCHEMBL2658556 0.79 MAPT (0.65) ALDH1A1KDM4EPOLBTDP1MAPT
SCHEMBL1143469 0.78 KDM4E (0.67) ALDH1A1KDM4EPOLBTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495023-B2 Thio semicarbazone and semicarbozone inhibitors of cysteine proteases and methods of their use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-02-24 US claimed
US-20040132807-A1 Aurones as telomerase inhibitors PHARMACIA ITALIA SPA (IT) 2004-07-08 US claimed
WO-2024103400-A1 POLYCYCLIC COMPOUND AS GPR75 ACTIVATOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF 水木未来(北京)科技有限公司 2024-05-23 WO disclosed
CN-117820303-A Tetrahydroacridine-9 carboxylic acid derivative and preparation method and application thereof 中国药科大学 2024-04-05 CN disclosed
EP-3226858-B1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS PROCOMCURE BIOTECH GMBH (AT) 2021-02-03 EP disclosed
US-10456379-B2 Imidazole-based antimicrobial agents PROCOMCURE BIOTECH GMBH (AT) 2019-10-29 US disclosed
US-10322110-B2 Imidazole-based antimicrobial agents PROCOMCURE BIOTECH GMBH (AT) 2019-06-18 US disclosed
US-9872911-B2 Alpha-aminoamidine polymers and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-01-23 US disclosed
US-9872911-B2 Alpha-aminoamidine polymers and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-01-23 US disclosed
US-20170368032-A1 Imidazole-Based Antimicrobial Agents PROCOMCURE BIOTECH GMBH (AT) 2017-12-28 US disclosed
US-20170334887-A1 Imidazole-Based Antimicrobial Agents PROCOMCURE BIOTECH GMBH (AT) 2017-11-23 US disclosed
WO-2002015662-A2 QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS PHARMACIA & UPJOHN COMPANY (US) 2002-02-28 WO disclosed
WO-2002017358-A2 QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) PHARMACIA & UPJOHN COMPANY (US) 2002-02-28 WO disclosed
US-20020010169-A1 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2002-01-24 US disclosed
WO-2001079187-A2 SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES CYTOVIA, INC. (US) 2001-10-25 WO disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed
WO-2000032598-A9 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY STRUCTURAL BIOINFORMATICS INC (US) 2000-11-30 WO disclosed
WO-2000053313-A2 LANTHANIDE CATALYSTS FOR SYNTHESIS OF COMPOUNDS AND COMBINATORIAL LIBRARIES ARQULE, INC. (US) 2000-09-14 WO disclosed
WO-2000032598-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY STRUCTURAL BIOINFORMATICS INC. (US) 2000-06-08 WO disclosed
US-3962284-A 3-(5-ARYL-2-FURYL)-3-HYDROXYPROPIONIC ACIDS AND ETHYL ESTERS MORTON-NORWICH PRODUCTS, INC. (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334887-A1 Imidazole-Based Antimicrobial Agents TLR5, NISCH, SLC11A2 ALDH1A1 1629/4885KDM4E 2893/4885POLB 1637/4885
US-10456379-B2 Imidazole-based antimicrobial agents TLR5, NISCH, SLC11A2 ALDH1A1 1629/4885KDM4E 2893/4885POLB 1637/4885
US-10322110-B2 Imidazole-based antimicrobial agents ARG1, SLC11A2, IKZF3 ALDH1A1 1211/4885KDM4E 1072/4885POLB 3215/4885
US-20040132807-A1 Aurones as telomerase inhibitors TERT, TERF2, TERF2IP ALDH1A1 1344/4885KDM4E 818/4885POLB 175/4885
US-20020010169-A1 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP1, CASP14, CASP4 ALDH1A1 832/4885KDM4E 1882/4885POLB 4060/4885
US-20170368032-A1 Imidazole-Based Antimicrobial Agents TLR5, NISCH, SLC11A2 ALDH1A1 1629/4885KDM4E 2893/4885POLB 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.